Leo Pharma will not use acquisition option after candidate disappoints in phase III trial

Leo Pharma partner Pellepharm's drug patidegib has not generated sufficiently convincing phase III data for the dermatology group to utilize its acquisition option and take over the candidate – and the company.

Photo: Leo Pharma / PR

A Danish billion-kroner acquisition of Californian biotech company Pellepharm will not be happening.

Leo Pharma confirms to MedWatch that the company has decided not to utilize the acquisition option it secured in 2018, which would have allowed it to acquire its US partner Pellepharm. The agreement concerned a collaboration to develop patidegib, a treatment for the rare skin condition Gorlin syndrome.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs